IDYAIDEAYA Biosciences, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+11% of shares).
Choppy, but holding above its 200-day average. Price is +6% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How IDYA is trading
IDEAYA Biosciences, Inc. is +40% over the past year while the S&P 500 is +18%: 22 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +6.5%
vs 200-day average · close to trend
- RSI (14)
- 37
RSI (14) · neutral
- Below its 52-week high
- 15%
Below its 52-week high
Details›
- Last close2026-10-09
- $36.12
- 1 monthS&P 500 +2.7%
- −3.5%
- 1 yearS&P 500 +18%
- +40%
- 5 yearsS&P 500 +88%
- +43%
- vs 50-day average$37.97
- −4.9%
- 52-week high
- $42.48
- 52-week low
- $25.67
- Annualised volatility
- 50%
| Year | Return |
|---|---|
| 2026 (year to date) | +4.5% |
| 2025 | +35% |
| 2024 | −28% |
| 2023 | +96% |
| 2022 | −23% |
| 2021 | +69% |
| 2020 | +87% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 3 of 7 | +1.9% |
| Feb | 7 | 4 of 7 | −5.6% |
| Mar | 7 | 2 of 7 | −11% |
| Apr | 7 | 3 of 7 | +6.2% |
| May | 7 | 4 of 7 | +15% |
| Jun | 8 | 6 of 8 | +11% |
| Jul | 8 | 4 of 8 | +2.3% |
| Aug | 8 | 3 of 8 | −1.5% |
| Sep | 8 | 5 of 8 | +9.4% |
| Oct | 8 | 3 of 8 | −5.3% |
| Nov | 7 | 6 of 7 | +12% |
| Dec | 7 | 4 of 7 | +1.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.